Wegovy results, month by month

STEP 1 recorded an average loss of about 15% of body weight over 68 weeks. STEP UP reached about 20.7% at the higher dose. Here is how that unfolds in real months.

Person in trainers walking down steps

Month 1: the quiet month

On 0.25 mg, expect appetite shifts more than scale shifts, typically 2 to 3% of body weight. The starter dose exists to build tolerance, and judging Wegovy by month one is the most common mistake new patients make.

Months 2 to 3: finding the rhythm

Through 0.5 mg and 1 mg, steady weekly loss of 0.5 to 1 kg becomes typical. This is when eating patterns reshape themselves: smaller portions feel natural rather than forced. Defend your muscle now with the protein guide.

Months 4 to 6: the steep middle

Reaching 1.7 mg and 2.4 mg, most responders pass 8 to 10% of starting weight. Plateaus arrive for almost everyone at some point here, brief, normal, and covered in the plateau guide.

Months 7 to 12: consolidating

In STEP 1, the 2.4 mg arm averaged about 15% loss at week 68. Roughly a third of participants lost 20% or more. The SELECT trial added a striking finding beyond weight: a 20% reduction in major cardiovascular events in people with existing heart disease.

Next comes the phase that decides everything: maintenance.

Why results vary

Genetics, sleep, protein, movement, stress and other medicines all move the number. The fairest expectation for someone who stays the course: 10 to 15% over a year, sometimes more. Your check-ins track your curve against this range so adjustments happen early, not after months of frustration.

The STEP 1 curve, simplified

Average body weight change over 68 weeks in STEP 1 (semaglutide 2.4 mg, with diet and activity support).

Weeks of treatment: share of total loss. The curve flattens after month 12 as your body settles at its new weight.

Continue reading

Wegovy pen with box

Wegovy plan from £69 a month

Weekly injection, semaglutide. Price covers the medicine, prescriber review, monthly check-ins and tracked delivery.

See the Wegovy plan

Check if treatment suits youFree health check. You pay nothing until a prescriber approves.

Check your eligibility

About this page

Written by
Able Clinic editorial team
Clinical review
Pharmacy team at Curb Healthcare Ltd, GPhC 9012581
Last reviewed

Each page is checked against the UK licence for the medicine. Read our editorial policy.

Sources

  1. NICE TA875: semaglutide for managing overweight and obesity
  2. STEP 1 trial, New England Journal of Medicine 2021
  3. SELECT trial (cardiovascular outcomes), NEJM 2023
  4. Electronic medicines compendium: Wegovy product information
  5. MHRA Yellow Card scheme
Check your eligibility